vaccines-gynecologic-oncology-2018-posters

Page 84

Journal of Clinical Immunology and Allergy

ISSN: 2471-304X

E u r o p e a n C o n g r e s s o n

Vaccines & Vaccination

and Gynecologic Oncology

Vaccines & Vaccination and Gynecologic Oncology 2018

O c t o b e r 2 6 - 2 7 , 2 0 1 8

B u d a p e s t , H u n g a r y

eisseria meningitidis causes severe, often fatal septicemia and meningitis. New polysaccharide-conjugate vaccines against four

serogroups (ACWY) are now in use in many countries due to increase in W disease and epidemiological unpredictability. Since

serogroup B contributes significantly to the burden of meningococcal disease in many industrialized and developing countries where

both epidemic and endemic serogroup B infections occur, new vaccines are available against this serogroup as well. Vaccines effective

against specific strains responsible for serogroup B disease have been licensed and have been included in National Immunization Pro-

grams with great success. The epidemiology and pathogenesis of meningococcal disease are detailed, along with discussion of the

new advances on vaccine prevention of ABCWY meningococcal disease.

Meningococcal Vaccines

Javier Casellas

Vaccine Expert Consultant, Argentina

Journal of Clinical Immunology and Allergy, Volume: 4

DOI: 10.21767/2471-304X-C2-006

Euro Vaccines 2018